Bayer begins Phase II trial with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumors Ruchika Sharma5 March 2025 9:00 AM ISTBerlin: Bayer has announced that the first patient has been enrolled in the global Phase II panSOHO study, an open-label clinical trial,...
Bayer gets Breakthrough Therapy designation in China for lung cancer drug BAY 2927088 Ruchika Sharma15 Jun 2024 10:00 AM ISTBerlin: Bayer has announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has...
Bayer gets USFDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations Ruchika Sharma29 Feb 2024 1:30 PM ISTBAY 2927088 was derived from Bayer's long-standing strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA.
